170 related articles for article (PubMed ID: 30896830)
1. Survivin overexpression in head and neck squamous cell carcinomas as a new therapeutic target (Review).
Frassanito MA; Saltarella I; Vinella A; Muzio LL; Pannone G; Fumarulo R; Vacca A; Mariggiò MA
Oncol Rep; 2019 May; 41(5):2615-2624. PubMed ID: 30896830
[TBL] [Abstract][Full Text] [Related]
2. Highlights in Head and Neck Cancer.
Chau NG; Tishler RB; Haddad RI
JAMA Oncol; 2017 Apr; 3(4):441-442. PubMed ID: 27893016
[No Abstract] [Full Text] [Related]
3. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
4. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
Galot R; Le Tourneau C; Guigay J; Licitra L; Tinhofer I; Kong A; Caballero C; Fortpied C; Bogaerts J; Govaerts AS; Staelens D; Raveloarivahy T; Rodegher L; Laes JF; Saada-Bouzid E; Machiels JP
Ann Oncol; 2018 Dec; 29(12):2313-2327. PubMed ID: 30307465
[TBL] [Abstract][Full Text] [Related]
5. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
[TBL] [Abstract][Full Text] [Related]
6. Survivin expression in head and neck squamous cell carcinomas is frequent and correlates with clinical parameters and treatment outcomes.
Münscher A; Prochnow S; Gulati A; Sauter G; Lörincz B; Blessmann M; Hanken H; Böttcher A; Clauditz TS
Clin Oral Investig; 2019 Jan; 23(1):361-367. PubMed ID: 29671054
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cell biomarkers for head and neck squamous cell carcinoma: A bioinformatic analysis.
Xiao M; Liu L; Zhang S; Yang X; Wang Y
Oncol Rep; 2018 Dec; 40(6):3843-3851. PubMed ID: 30542719
[TBL] [Abstract][Full Text] [Related]
8. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
[TBL] [Abstract][Full Text] [Related]
9. Trace of survivin in cancer.
Shojaei F; Yazdani-Nafchi F; Banitalebi-Dehkordi M; Chehelgerdi M; Khorramian-Ghahfarokhi M
Eur J Cancer Prev; 2019 Jul; 28(4):365-372. PubMed ID: 29847456
[TBL] [Abstract][Full Text] [Related]
10. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma.
Ryumon S; Okui T; Kunisada Y; Kishimoto K; Shimo T; Hasegawa K; Ibaragi S; Akiyama K; Thu Ha NT; Monsur Hassan NM; Sasaki A
Oncol Rep; 2019 Dec; 42(6):2611-2621. PubMed ID: 31638244
[TBL] [Abstract][Full Text] [Related]
11. Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
El Rassy E; Assi T; Bakouny Z; El Karak F; Pavlidis N; Ghosn M
Future Oncol; 2019 Mar; 15(8):909-923. PubMed ID: 30669875
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
13. Autophagy induction contributes to GDC-0349 resistance in head and neck squamous cell carcinoma (HNSCC) cells.
Zhou Y; Peng Y; Tang H; He X; Wang Z; Hu D; Zhou X
Biochem Biophys Res Commun; 2016 Aug; 477(2):174-80. PubMed ID: 27291151
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death.
Park YM; Go YY; Shin SH; Cho JG; Woo JS; Song JJ
PLoS One; 2018; 13(9):e0203069. PubMed ID: 30212479
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
[TBL] [Abstract][Full Text] [Related]
18. Paeoniflorigenone regulates apoptosis, autophagy, and necroptosis to induce anti-cancer bioactivities in human head and neck squamous cell carcinomas.
Park KR; Lee H; Kim SH; Yun HM
J Ethnopharmacol; 2022 Apr; 288():115000. PubMed ID: 35051602
[TBL] [Abstract][Full Text] [Related]
19. A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
Kina S; Kawabata-Iwakawa R; Miyamoto S; Arasaki A; Sunakawa H; Kinjo T
J Drug Target; 2021 Dec; 29(10):1118-1127. PubMed ID: 33979258
[TBL] [Abstract][Full Text] [Related]
20. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
Szturz P; Seiwert TY; Vermorken JB
J Clin Oncol; 2017 Jul; 35(20):2229-2231. PubMed ID: 28471725
[No Abstract] [Full Text] [Related]
[Next] [New Search]